These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
684 related articles for article (PubMed ID: 25435079)
1. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
4. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]. Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454 [TBL] [Abstract][Full Text] [Related]
5. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Jotte RM; Spigel DR Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719 [TBL] [Abstract][Full Text] [Related]
6. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
7. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. Hirsh V BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538 [TBL] [Abstract][Full Text] [Related]
8. [Mechanism of action and preclinical development of afatinib]. Diz Taín P; González AL; García-Palomo A Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242 [TBL] [Abstract][Full Text] [Related]
9. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Zhang X; Munster PN Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047 [TBL] [Abstract][Full Text] [Related]
11. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Sun H; Wu YL Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844 [TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Lavacchi D; Mazzoni F; Giaccone G Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835 [TBL] [Abstract][Full Text] [Related]
13. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Roskoski R Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736 [TBL] [Abstract][Full Text] [Related]
14. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584 [TBL] [Abstract][Full Text] [Related]
16. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973 [TBL] [Abstract][Full Text] [Related]
17. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644 [TBL] [Abstract][Full Text] [Related]
18. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. Hamid O J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154 [TBL] [Abstract][Full Text] [Related]
19. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cohen RB Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to HER family targeting antibodies. Kruser TJ; Wheeler DL Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]